NYtor
NYtor is a knowledge-driven and reliable developer of innovative molecular diagnostic assays, employing a team of highly skilled professionals with over 30 years of experience. The company focuses on developing tailor-made applications, including qPCR and point-of-care assays, with a main focus on early cancer screening and pathogen detection. They emphasize long-term relationships and personal interactions, and operate in compliance with ISO 13485:2016 regulations.
Industries
Nr. of Employees
small (1-50)
NYtor
Berg en Dalseweg 199, 6522 BJ Nijmegen, The Netherlands
Products
Multiplex qPCR kit for detection of T. vaginalis, M. genitalium and macrolide resistance mutations (RUO)
Research-use-only multiplex real-time PCR kit for simultaneous detection and differentiation of T. vaginalis, Mycoplasma genitalium and prevalent mutations associated with macrolide resistance.
Multiplex qPCR kit for Mycoplasma genitalium and fluoroquinolone resistance mutations (RUO)
Research-use-only multiplex real-time PCR kit for detection of Mycoplasma genitalium and prevalent fluoroquinolone resistance mutations.
Multiplex qPCR kit for N. gonorrhoeae and fluoroquinolone resistance mutations (RUO)
Research-use-only multiplex real-time PCR kit for detection of Neisseria gonorrhoeae and prevalent fluoroquinolone resistance mutations.
Multiplex qPCR kit for detection of T. vaginalis, M. genitalium and macrolide resistance mutations (RUO)
Research-use-only multiplex real-time PCR kit for simultaneous detection and differentiation of T. vaginalis, Mycoplasma genitalium and prevalent mutations associated with macrolide resistance.
Multiplex qPCR kit for Mycoplasma genitalium and fluoroquinolone resistance mutations (RUO)
Research-use-only multiplex real-time PCR kit for detection of Mycoplasma genitalium and prevalent fluoroquinolone resistance mutations.
Multiplex qPCR kit for N. gonorrhoeae and fluoroquinolone resistance mutations (RUO)
Research-use-only multiplex real-time PCR kit for detection of Neisseria gonorrhoeae and prevalent fluoroquinolone resistance mutations.
Services
Tailor-made development of nucleic acid amplification assays from target selection to prototype kit, including in silico design, wet-lab development and design freeze.
Optimization of primers/probes, reagent selection, concentration tuning and multiplex assay assembly to improve sensitivity and robustness.
Prototype batch production, QC1/QC2 checks, verification against customer specifications and preparation of an assay design history file for transfer.
Adaptation and validation of assays for portable and handheld platforms, field testing and integration with mobile data portals.
Participation in multi-partner consortia, support for collaborative grant applications and execution of funded projects to develop integrated diagnostic solutions.
Tailor-made development of nucleic acid amplification assays from target selection to prototype kit, including in silico design, wet-lab development and design freeze.
Optimization of primers/probes, reagent selection, concentration tuning and multiplex assay assembly to improve sensitivity and robustness.
Prototype batch production, QC1/QC2 checks, verification against customer specifications and preparation of an assay design history file for transfer.
Adaptation and validation of assays for portable and handheld platforms, field testing and integration with mobile data portals.
Participation in multi-partner consortia, support for collaborative grant applications and execution of funded projects to develop integrated diagnostic solutions.
Expertise Areas
- Molecular diagnostic assay development
- Real-time qPCR and multiplex assay optimization
- Point-of-care diagnostics and field-deployable testing
- Lab-on-a-chip and nanoscale biochip development
Key Technologies
- Real-time quantitative PCR (qPCR)
- Isothermal amplification (e.g., LAMP)
- Digital PCR (dPCR)
- Lab-on-a-chip / microfluidic biochips
News & Updates
Announcement of NYtor becoming a subsidiary of HatchTech Group as of April 1st, 2024.
Discussion on molecular tools used for assessing microbial water quality.
High resistance rates in Mycoplasma genitalium in France, with NYtor's involvement.
Development of rapid tests for antibiotic resistance in Mycoplasma genitalium.
Announcement of NYtor becoming a subsidiary of HatchTech Group as of April 1st, 2024.
Discussion on molecular tools used for assessing microbial water quality.
High resistance rates in Mycoplasma genitalium in France, with NYtor's involvement.
Development of rapid tests for antibiotic resistance in Mycoplasma genitalium.